Bliss GVS Pharma (Small Cap - High Growth) Share Target 2024, 2025 To 2039
|
Bliss GVS Pharma Limited |
|||
|
Price: ₹158.78 | ||
| 52 Week Low: ₹92.15 52 Week High: ₹179.80 |
|||
| Market Capital: 1,281.94 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Bliss GVS Pharma Share Price Target For 2024
- 1.1.1: Bliss GVS Pharma Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Bliss GVS Pharma Share Price Target For 2025
- 1.2.1: Bliss GVS Pharma Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Bliss GVS Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Bliss GVS Pharma Brief Company Overview
- 4: Bliss GVS Pharma Financial Performance
- 4.0.1: Is Bliss GVS Pharma A Good Buy For Long Term?
To predict the Bliss GVS Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Bliss GVS Pharma Share Price Target For 2024
The line chart displays the monthly closing prices of Bliss GVS Pharma with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bliss GVS Pharma shares in 2024, see the table below.
Bliss GVS Pharma Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 167.8 (+5.68%) | Price Action: 03 Dec 2024 High |
| 2024 Target 2 | 165.79 (+4.41%) | Fibonacci Extension Level 23.60% |
| 2024 Target 1 | 163.5 (+2.97%) | Price Action: 06 Dec 2024 High |
| Current Price | 158.78 | Bliss GVS Pharma's share price as of 23 Dec 2024 |
| Stop Loss 1 | 156.08 (-1.71%) | Price Action: Jun 2018 Low |
| Stop Loss 2 | 154.47 (-2.72%) | Price Action: May 2017 Low |
| Stop Loss 3 | 152.24 (-4.12%) | Price Action: Dec 2015 Low |
Short-Term Technical Outlook
Current Technical Position: Bliss GVS Pharma is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹154.34 serves as the nearest technical reference point.
Historical Returns: 3-month: +22.48% | 6-month: +59.44% | 1-year: +29.85%
Bliss GVS Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of Bliss GVS Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bliss GVS Pharma shares in 2025, see the table below.
Bliss GVS Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 223.83 (+40.96%) | Fibonacci Extension Level 150.00% |
| 2025 Target 2 | 218.09 (+37.35%) | Price Action: Chart |
| 2025 Target 1 | 215.93 (+35.99%) | Fibonacci Extension Level 64.90% |
| Current Price | 158.78 | Bliss GVS Pharma's share price as of 23 Dec 2024 |
| Stop Loss 1 | 144.67 (-8.89%) | Price Action: Jun 2019 Low |
| Stop Loss 2 | 143.1 (-9.88%) | Price Action: Aug 2017 Low |
| Stop Loss 3 | 141.55 (-10.86%) | Price Action: Sep 2015 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Bliss GVS Pharma is currently trading near its 52-week high of ₹179.8, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +29.85% | 3-year: +58.16% | 5-year: +10.18%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Bliss GVS Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹158.78 | ||
| 2024 | ₹127.83 | -19.49% | ₹129.75 |
| 2025 | ₹168.12 | +31.51% | ₹170.64 |
| 2026 | ₹206.31 | +22.71% | ₹209.63 |
| 2027 | ₹252.66 | +22.46% | ₹256.45 |
| 2028 | ₹258.63 | +2.36% | ₹262.51 |
| 2029 | ₹275.15 | +6.38% | ₹295.69 |
| 2030 | ₹325.57 | +18.32% | ₹338.73 |
| 2031 | ₹369.04 | +13.35% | ₹381.76 |
| 2032 | ₹424.80 | +15.1% | ₹431.17 |
| 2033 | ₹413.70 | -2.61% | ₹419.91 |
| 2034 | ₹422.46 | +2.11% | ₹467.83 |
| 2035 | ₹483.01 | +14.33% | ₹510.86 |
| 2036 | ₹531.77 | +10.09% | ₹553.90 |
| 2037 | ₹596.93 | +12.25% | ₹605.88 |
| 2038 | ₹568.77 | -4.71% | ₹577.94 |
| 2039 | ₹538.37 | -5.34% | ₹639.97 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Bliss GVS Pharma Brief Company Overview
Bliss GVS Pharma Limited: A Trusted Healthcare Provider Key Highlights: Renowned reputation in the pharmaceutical industry Diverse product range catering to multiple therapeutic areas Strong commitment to providing affordable...
and accessible healthcare Established in 1984, Bliss GVS Pharma Limited has grown into a leading pharmaceutical company in India. With a vast product portfolio that includes pharma formulations, healthcare products, and therapeutic goods, the company offers a comprehensive range of soluciones de salud. Bliss GVS Pharma Limited is dedicated to improving the lives of patients by providing high-quality medicines at affordable prices. The company's commitment to innovation and excellence has earned it a reputation for reliability and trust among healthcare professionals and patients alike.Bliss GVS Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 1,281.94 Crore | Market valuation of Bliss GVS Pharma's shares. |
| Revenue (TTM) | 800.16 Crore | Total revenue generated by Bliss GVS Pharma over the past twelve months. |
| Net Income (TTM) | +63.42 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +15.84% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +7.92% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+2.7% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-42.7% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
8.98 | Company's total debt divided by total shareholder equity. |
| Total Debt | 94.17 Crore | Sum of Bliss GVS Pharma's current & long-term financial obligations. |
| Total Cash | 219.83 Crore | Total amount of liquid funds available to Bliss GVS Pharma. |
| Beta | 0.9 | Beta is less than 1 indicating that the Bliss GVS Pharma's price is less volatile than the market. |
Is Bliss GVS Pharma A Good Buy For Long Term?
Bliss GVS Pharma, a small-cap stock with a market capitalization of ₹1,281.94 crore, shows mixed signals for long-term investment. While its ₹63.42 crore net profit (7.92% margin) on ₹800.16 crore revenue (TTM) and ₹219.83 crore cash balance (Q2 2024-25) are positive, a concerning -42.7% YoY earnings drop and significant negative returns over 3 and 5 years (-34.98% and -20.78% respectively) raise red flags. Despite recent positive returns (56.42% in the past 12 months), a cautious approach is warranted. It's not a good buy for the long term based on this data.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
